life scienc tool diagnost earn
ep exce consensu avtr ep ahead
estim weaker revenu off-set profit beat driven
primarili factor line also initi guidanc call
ebitda billion consensu billion reflect org
revenu growth essenti line estimate view
encourag rais ep reflect lower
profit off-set lower tax rate importantli make monument
chang organ revenu growth assumpt
revenu profit shi org revenue america
disappoint vs estimate strength biopharma edu off-set soft
government healthcar europ also fell short vs estimate
includ hsd biopharma growth dd growth healthcar partial off-set
weak edu government amea bright spot vs estimate management
note exit dd growth biopharma gross margin rose bp bp
plan administr expens bp better plan bp
ebit margin expand bp bp better estim oper cash
flow million help fund million debt pay net leverag
reiter outperform share ipo vs
expect remain low rel lst peer view latest report
like better fear guidanc call organ growth in-
line expect announc departur head america
releas encourag avtr decis separ amea region two
commerci sub-seg new evp sven henrichwark respons grow
presenc apac focu china remind remain under-index apac
rel peer sale broader amea region
remain posit bias rise exposur faster-grow end market
innov greater penetr higher margin proprietari consum vwr
commerci synergi focu call guidanc leadership shift end-
custom perform emerg market growth synergi captur risk includ
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
global manufactur distributor product servic
custom locat focus biopharma
life scienc end market gener
estim billion revenu
blue sky scenario predic better-than-expect
synergi captur relat acquisit
continu improv effort driven busi
acceler penetr growth emerg market well
sustain strength biopharma end-market
grey sky scenario base lower-than-expect
synergi captur relat acquisit
integration-rel miscu slow spend across broader
biopharma end-market heighten competit
 close
compani mention price
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
